FLT3 and acute myeloid leukemia: Collectively, these findings underscore the critical role of metabolic rewiring in TKI resistance and provide a strong rationale for combined therapeutic strategies targeting both oncogenic signaling and metabolic dependencies to achieve durable responses in FLT3-mutated AML.